FGFR3-specific monoclonal antibodies, vofatamab, showed great effectiveness in inhibiting the progression of FGFR3-associated bladder cancer,109 which provides the potential for the usage of FGFR3 antibodies in treating ACH. Here, FGFR3 is linked to urinary bladder cancer.